Grifols holds its Extraordinary General Shareholders’ Meeting with over 70% of the company’s share capital represented

Grifols shareholders approve a bonus share issue as a remuneration formula for shareholders

- The capital increase will be achieved through the issue of 29,687,658 new Class B shares, fully paid up and charged to voluntary reserves
- Each shareholder will receive free of charge 1 new Class B share for every 10 old shares, irrespective of whether these are Class A or Class B
- Grifols keeps its commitment to rewarding shareholders at the same time that increases the liquidity of its non-voting shares

Barcelona, December 2, 2011: The shareholders of Grifols (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS), the third-largest company in the world by production of plasma-derived biological medicines, have approved by majority a bonus issue of fully paid up shares as a formula for their remuneration. The bonus issue of new non-voting shares (Class B) was the main proposal included on the agenda of the Extraordinary General Meeting held today on second call, with 505 shareholders represented, holding 155,355,224 Class A and 58,848,128 Class B shares, representing 72.91% and 70.22% respectively of the company’s share capital.

This approval will allow each shareholder to receive free of charge 1 new Class B share for every 10 old shares, irrespective of whether these are Class A or Class B. The approved capital increase for a nominal value of 2.96 million euros, will consist of the issue and release of 29,687,658 new non-voting shares (Class B) with a nominal value of 0.10 euros each, with no premium and charged to voluntary reserves.

With this bonus issue of fully paid up shares, Grifols keeps its commitment to remunerate its shareholders, who demonstrated their confidence in the management of the company and its future by approving the allocation to voluntary reserves of the total profits of Grifols S.A. in 2010 (63.5 million euros). Despite the need for the reinvestment of profits derived from the Talecris acquisition, the group has always been committed towards finding other formulae to remunerate its shareholders.

The votes delegated to the Board of Directors represented 71.18% of the company’s Class A share capital and 70.21% of the Class B shares, evidence of shareholders’
endorsement of all the items on the agenda, including various modifications to the company’s articles of association in order to bring these into line with the current Spanish Company’s Act (“Ley de Sociedades de Capital), and changes to the corporate website.

Currently, Grifols’ share capital totals 114.91 million euros, represented by 213,064,899 ordinary shares (Class A), and 83,811,688 non-voting shares (Class B). Upon completion of the share issue, Grifols’ share capital will total 117.88 million euros, represented by 213,064,899 ordinary shares (Class A) and 113,499,346 non-voting shares (Class B).

**Grifols “Class B” shares carry the same financial rights as ordinary shares and a preferred dividend**

Newly issued non-voting Grifols shares (Class B) will be traded in Spain and on the United States in NASDAQ via ADS (American Depositary Shares). In addition to bearing the same dividend and carrying the same financial rights as ordinary shares, they have additional rights including a preferred dividend.

The capital increase will also increase the liquidity of Grifols’ Class B shares, with the aim of improving its market trading. The group’s Class B shares are currently (01/12/2011) trading at 8.68 euros per share.

**About Grifols**

Grifols, with presence in more than 90 countries, is a global pharmaceutical company specializing in the Hemotherapy sector, the medical discipline that treats disease using blood components. The company’s class A shares have been listed on the Spanish Stock Exchange (MCE:GRF) since 2006 and have been part of the Ibex-35 since 2008. In 2011, the company listed non-voting class B shares on the Mercado Continuo (MCE:GRF.P) and in NASDAQ-United States via ADRs (NASDAQ: GRFS).

Grifols is the third company worldwide in plasma protein therapies, in terms of capacity after the recent purchase of Talecris, with a balanced and diversified range of products. In upcoming years, the company will strengthen its leadership in the industry as a vertically integrated company, as a result of on-going investment plans. Grifols is the world leader in plasma collection with 147 plasma donor centers in the United States to ensure a continued and reliable supply of human plasma for the production of plasma therapies. In terms of production capacity (fractionation), Grifols owns and operates several plants in Spain and the United States that allow it to respond to the growing market demand. Grifols’ sustained growth will be supported by a strong presence in the United States, Canada and Europe, where upcoming sales are expected to represent 53%, 7% and 26%, respectively.
The facts and figures contained in this report which do not refer to historical data are "projections and forward-looking statements". The words and expressions like "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "try to achieve", "estimate", "future" and similar expressions, insofar as they are related to Grifols Group, are used to identify projections and forward-looking statements. These expressions reflect the assumptions, hypothesis, expectations and anticipations of the management team at the date of preparation of this report, which are subject to a number of factors that could make the real results differ considerably. The future results of Grifols Group could be affected by events related to its own activity, such as shortages of raw materials for the manufacture of its products, the launch of competitive products or changes in the regulations of markets in which it operates, among others. At the date of preparation of this report Grifols Group has adopted the measures it considers necessary to offset the possible effects of these events. Grifols, S.A. does not assume any obligation to publicly inform, review or update any projections and forward-looking statements to adapt them to facts or circumstances following the preparation of this report, except as specifically required by law.

This document does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of the Spanish Securities Market Law 24/1988, of July 28, the Royal Decree-Law 5/2005, of March 11, and/or Royal Decree 1310/2005, of November 4, and its implementing regulations.